Cargando…

Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020

BACKGROUND: Leukemia contributes significantly to the global cancer burden. Due to the importance of evaluating improvements in leukemia outcomes, the current study aimed to examine the variations in mortality-to-incidence ratio (MIR) between genders and association of MIR with the health expenditur...

Descripción completa

Detalles Bibliográficos
Autores principales: Amini, Maedeh, Sharma, Rajesh, Jani, Chinmay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440892/
https://www.ncbi.nlm.nih.gov/pubmed/37605241
http://dx.doi.org/10.1186/s13690-023-01154-8
_version_ 1785093250508390400
author Amini, Maedeh
Sharma, Rajesh
Jani, Chinmay
author_facet Amini, Maedeh
Sharma, Rajesh
Jani, Chinmay
author_sort Amini, Maedeh
collection PubMed
description BACKGROUND: Leukemia contributes significantly to the global cancer burden. Due to the importance of evaluating improvements in leukemia outcomes, the current study aimed to examine the variations in mortality-to-incidence ratio (MIR) between genders and association of MIR with the health expenditures in selected countries. METHODS: The leukemia incidence and mortality rates were extracted from the GLOBOCAN 2020 database. In total, 56 countries were included based on the data quality reports and the exclusion of missing data. The associations of MIR and changes in MIR over time ([Formula: see text] MIR) with the human development index (HDI), current health expenditure (CHE) per capita, and current health expenditure as a percentage of gross domestic product (CHE/GDP) were investigated using Spearman’s rank correlation coefficient. RESULTS: In 2020, an estimated 474,519 new cases of leukemia were diagnosed globally, and 311,594 deaths occurred due to the disease. Male patients exhibited a higher incidence and mortality of leukemia compared to females on a global scale. Our analysis revealed that the MIRs were the highest and lowest in Egypt (0.79) and the United States (0.29), respectively. Remarkably, countries with greater HDI, higher CHE per capita, and a higher CHE/GDP tended to have lower MIR in both genders and within gender-specific subgroups. The δMIR demonstrated a significant negative correlation with HDI and CHE per capita, whereas no significant associations were observed among female patients for CHE/GDP. Besides, all three indicators showed trends towards negative correlations with δMIR among males, though these trends were not statistically significant (p>0.05). CONCLUSIONS: Generally, leukemia MIRs tended to be most favorable (i.e., lower) in countries with high HDI and high health expenditure. The gender differences observed in leukemia outcomes may reflect the potential influence of social, material, behavioral, and biological factors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13690-023-01154-8.
format Online
Article
Text
id pubmed-10440892
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104408922023-08-22 Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020 Amini, Maedeh Sharma, Rajesh Jani, Chinmay Arch Public Health Research BACKGROUND: Leukemia contributes significantly to the global cancer burden. Due to the importance of evaluating improvements in leukemia outcomes, the current study aimed to examine the variations in mortality-to-incidence ratio (MIR) between genders and association of MIR with the health expenditures in selected countries. METHODS: The leukemia incidence and mortality rates were extracted from the GLOBOCAN 2020 database. In total, 56 countries were included based on the data quality reports and the exclusion of missing data. The associations of MIR and changes in MIR over time ([Formula: see text] MIR) with the human development index (HDI), current health expenditure (CHE) per capita, and current health expenditure as a percentage of gross domestic product (CHE/GDP) were investigated using Spearman’s rank correlation coefficient. RESULTS: In 2020, an estimated 474,519 new cases of leukemia were diagnosed globally, and 311,594 deaths occurred due to the disease. Male patients exhibited a higher incidence and mortality of leukemia compared to females on a global scale. Our analysis revealed that the MIRs were the highest and lowest in Egypt (0.79) and the United States (0.29), respectively. Remarkably, countries with greater HDI, higher CHE per capita, and a higher CHE/GDP tended to have lower MIR in both genders and within gender-specific subgroups. The δMIR demonstrated a significant negative correlation with HDI and CHE per capita, whereas no significant associations were observed among female patients for CHE/GDP. Besides, all three indicators showed trends towards negative correlations with δMIR among males, though these trends were not statistically significant (p>0.05). CONCLUSIONS: Generally, leukemia MIRs tended to be most favorable (i.e., lower) in countries with high HDI and high health expenditure. The gender differences observed in leukemia outcomes may reflect the potential influence of social, material, behavioral, and biological factors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13690-023-01154-8. BioMed Central 2023-08-21 /pmc/articles/PMC10440892/ /pubmed/37605241 http://dx.doi.org/10.1186/s13690-023-01154-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Amini, Maedeh
Sharma, Rajesh
Jani, Chinmay
Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020
title Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020
title_full Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020
title_fullStr Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020
title_full_unstemmed Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020
title_short Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020
title_sort gender differences in leukemia outcomes based on health care expenditures using estimates from the globocan 2020
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440892/
https://www.ncbi.nlm.nih.gov/pubmed/37605241
http://dx.doi.org/10.1186/s13690-023-01154-8
work_keys_str_mv AT aminimaedeh genderdifferencesinleukemiaoutcomesbasedonhealthcareexpendituresusingestimatesfromtheglobocan2020
AT sharmarajesh genderdifferencesinleukemiaoutcomesbasedonhealthcareexpendituresusingestimatesfromtheglobocan2020
AT janichinmay genderdifferencesinleukemiaoutcomesbasedonhealthcareexpendituresusingestimatesfromtheglobocan2020